Precigen (PGEN) Q2 2024 earnings summary

Executive summary

• PRGN-2012, a gene therapy for RRP, is the primary focus, with pivotal study data showing over 51% Complete Response and meeting primary safety and efficacy endpoints; the company aims for the first FDA approval in this indication.

• Strategic prioritization in August 2024 led to a workforce reduction of over 20%, pausing non-core and preclinical programs, and suspending ActoBio subsidiary operations.

• The company is preparing for a potential commercial launch in 2025, with global ambitions, manufacturing readiness, and a new Chief Commercial Officer appointed.

• Recent $31.4 million equity raise in August 2024 extends cash runway into early 2025, but substantial doubt remains about going concern.

• ActoBio shutdown resulted in significant impairment and severance charges, with IP available for transactions.

Financial highlights

• Q2 2024 net loss was $58.8 million ($0.23 per share), compared to $20.3 million ($0.08 per share) in Q2 2023; H1 2024 net loss was $82.5 million ($0.33 per share) vs. $43.1 million ($0.18 per share) in H1 2023.

• Revenues fell 59% year-over-year in Q2 to $0.7 million, mainly due to lower Exemplar service revenues.

• Operating expenses rose 169% to $61.6 million in Q2, driven by $34.5 million in impairment charges and higher R&D and SG&A costs.

• Cash and investments totaled $19.5 million as of June 30, 2024, with $9.3 million in cash and equivalents.

• Six-month net loss was $82.5 million, with operating cash outflows of $37.2 million.

Outlook and guidance

• On track to submit BLA for PRGN-2012 by end of 2024 under accelerated approval, targeting commercial launch in 2025.

• Confirmatory trial for PRGN-2012 is underway, with strong patient interest and rapid enrollment expected.

• Cash runway extends into early 2025 after equity raise; further cost reductions and non-dilutive financings under consideration.